作者
Chris Chun-Yiu Chan,Qian Guo,Jasper Fuk‐Woo Chan,Kaiming Tang,Jian‐Piao Cai,Kenn Ka‐Heng Chik,Yixin Huang,Mei Dai,Bo Qin,Chon Phin Ong,Allen Wing‐Ho Chu,Wan-Mui Chan,Jonathan Daniel Ip,Lei Wen,Jessica Oi‐Ling Tsang,Tong-Yun Wang,Yubin Xie,Zhenzhi Qin,Jianli Cao,Zi‐Wei Ye,Hin Chu,Kelvin Kai‐Wang To,Xing-Yi Ge,Tao Ni,Dong‐Yan Jin,Sheng Cui,Kwok-Yung Yuen,Shuofeng Yuan
摘要
There are only eight approved small molecule antiviral drugs for treating COVID-19. Among them, four are nucleotide analogues (remdesivir, JT001, molnupiravir, and azvudine), while the other four are protease inhibitors (nirmatrelvir, ensitrelvir, leritrelvir, and simnotrelvir-ritonavir). Antiviral resistance, unfavourable drug‒drug interaction, and toxicity have been reported in previous studies. Thus there is a dearth of new treatment options for SARS-CoV-2. In this work, a three-tier cell-based screening was employed to identify novel compounds with anti-SARS-CoV-2 activity. One compound, designated